Clinical progress SOLX has FDA-cleared TiSapphire 790nm laser and a Gold Shunt in IDE-enrolled trials, indicating near-term sales opportunities with ophthalmology clinics and hospital systems pursuing glaucoma management innovations.

Product pipeline An implantable IOP sensor under development through a Purdue University collaboration suggests cross-sell potential into surgical centers and research affiliates seeking integrated IOP monitoring solutions.

Market positioning As a glaucoma device manufacturer with a small-to-midsize team, SOLX may be pursuing niche ophthalmology accounts and early-adopter clinics that value novel IOP measurement and management technologies.

Funding signals Revenue is in the sub-1M range, signaling growth needs that can be supported by new channel partnerships, clinical distributors, and targeted outreach to mid-market ophthalmology groups and ASC networks.

Strategic partnerships Partnerships with academic institutions and collaboration with Purdue indicate readiness for co-development and research-funded trials, presenting opportunities to engage university-affiliated clinics and research centers for pilots and data-driven case studies.